Skip to main content

Table 2 Total SPM

From: Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

Site All cancers small cell lung cancer large cell neuroendocrine cancer
O E O/E 95% CI Excess risk O E O/E 95% CI Excess risk O E O/E 95% CI Excess risk
All sites 1361 887.49 1.53 1.45–1.62 83.11 1195 804.21 1.49 1.4–1.57 75.28 166 83.27 1.99 1.7–2.32 163.46
All solid tumours 1241 790.41 1.57 1.48–1.66 79.08 1083 716.6 1.51 1.42–1.6 70.58 158 73.81 2.14 1.82–2.5 166.34
Oral cavity and pharynx 30 20.08 1.50 1.01–2.13 1.74 28 18.1 1.55 1.03–2.24 1.91 2 1.97 1.02 0.12–3.68 0.07
 Floor of Mouth, and Gum and Other Mouth 13 4.08 3.19 1.7–5.45 1.57 13 3.69 3.52 1.88–6.02 1.79 0 0.39 0.00 0.00–9.54 −0.76
 Pharynx 8 2.86 2.79 1.21–5.51 0.9 7 2.58 2.71 1.09–5.58 0.85 1 0.28 3.59 0.09–20.02 1.43
Digestive System 227 165.17 1.37 1.2–1.57 10.85 201 149.43 1.35 1.17–1.54 9.93 26 15.75 1.65 1.08–2.42 20.26
 Esophagus 17 9.32 1.82 1.06–2.92 1.35 16 8.39 1.91 1.09–3.1 1.47 1 0.94 1.06 0.03–5.93 0.12
 Colon and Rectum 113 84.02 1.34 1.11–1.62 5.09 100 76.28 1.31 1.07–1.59 4.57 13 7.74 1.68 0.89–2.87 10.39
 Anus, Anal Canal and Anorectum 8 3.19 2.51 1.08–4.94 0.84 5 2.9 1.72 0.56–4.02 0.4 3 0.29 10.44 2.15–30.5 5.36
 Pancreas 46 25.96 1.77 1.3–2.36 3.52 41 23.42 1.75 1.26–2.38 3.39 5 2.54 1.97 0.64–4.59 4.85
Respiratory System 650 144.98 4.48 4.15–4.84 88.64 564 131.35 4.29 3.95–4.66 83.34 86 13.63 6.31 5.05–7.79 142.99
 Larynx 20 6.92 2.89 1.77–4.46 2.3 19 6.25 3.04 1.83–4.75 2.46 1 0.67 1.48 0.04–8.26 0.64
 Lung and Bronchus 627 136.6 4.59 4.24–4.96 86.07 543 123.79 4.39 4.03–4.77 80.75 84 12.82 6.55 5.23–8.12 140.65
Breast 86 122.17 0.70 0.56–0.87 −6.35 74 112.39 0.66 0.52–0.83 −7.39 12 9.78 1.23 0.63–2.14 4.38
 Female Breast 86 121.11 0.71 0.57–0.88 −6.16 74 111.44 0.66 0.52–0.83 −7.21 12 9.67 1.24 0.64–2.17 4.61
Female Genital System 20 47.09 0.42 0.26–0.66 −4.76 19 43.35 0.44 0.26–0.68 −4.69 1 3.74 0.27 0.01–1.49 −5.42
 Corpus and Uterus, NOS 4 26.93 0.15 0.04–0.38 −4.02 4 24.8 0.16 0.04–0.41 − 4.01 0 2.13 0.00 0–1.73 −4.21
Male Genital System 59 144.85 0.41 0.31–0.53 −15.07 49 130.36 0.38 0.28–0.5 −15.67 10 14.49 0.69 0.33–1.27 −8.87
 Prostate 57 143.35 0.40 0.3–0.52 −15.16 47 129.02 0.36 0.27–0.48 − 15.8 10 14.33 0.70 0.33–1.28 −8.56
Urinary System 117 76.03 1.54 1.27–1.84 7.19 104 68.35 1.52 1.24–1.84 6.87 13 7.68 1.69 0.9–2.89 10.51
 Urinary Bladder 68 45.07 1.51 1.17–1.91 4.02 59 40.43 1.46 1.11–1.88 3.58 9 4.64 1.94 0.89–3.68 8.61
 Kidney and Renal Pelvis 47 28.99 1.62 1.19–2.16 3.16 43 26.15 1.64 1.19–2.21 3.25 4 2.84 1.41 0.38–3.61 2.3
All Lymphatic and Hematopoietic Diseases 95 75.86 1.25 1.01–1.53 3.36 88 68.46 1.29 1.03–1.58 3.76 7 7.41 0.95 0.38–1.95 −0.8
 Lymphoma 24 38.88 0.62 0.4–0.92 −2.61 23 35.14 0.65 0.41–0.98 −2.34 1 3.74 0.27 0.01–1.49 −5.41
 Myeloma 5 13.46 0.37 0.12–0.87 −1.49 4 12.12 0.33 0.09–0.84 −1.56 1 1.34 0.75 0.02–4.15 −0.68
 Leukemia 66 23.52 2.81 2.17–3.57 7.46 61 21.19 2.88 2.2–3.7 7.67 5 2.33 2.15 0.7–5.01 5.28
  1. *O, observed numbers; E, expected numbers